Published in final edited form as:

Sleep Breath. 2017 March ; 21(1): 145–147. doi:10.1007/s11325-016-1388-y.

Effect of continuous positive airway pressure (CPAP) on glycemic control and variability in type 2 diabetes

Elena M Morariu¹, Eileen R Chasens², Patrick J Strollo Jr³, and Mary Korytkowski⁴

¹Division of Endocrinology, Diabetes and Metabolism, Department of Medicine University of Pittsburgh, 3601 Fifth Ave Suite 562, Pittsburgh, PA 15213, USA, Phone 412-586-9700

²School of Nursing, University of Pittsburgh, Pittsburgh, PA USA

³Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA USA

⁴Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA USA

Obstructive sleep apnea (OSA) has been reported as a comorbidity of type 2 diabetes (T2D) in up to 80 % of patients, depending on the population studied [1]. Correlations between OSA severity and glycemic control have been reported [1]; however, studies investigating the effect of treatment with continuous positive airway pressure (CPAP) on glycemic control have demonstrated conflicting results [2]. A meta-analysis of six prospective observational studies and randomized controlled trials showed an improvement in insulin sensitivity with CPAP treatment in subjects with T2D, but no effect on HbA1c [2]. Studies using continuous glucose monitoring (CGM) before and during CPAP therapy demonstrated improvements in glycemic control [3, 4]. The few prospective trials investigating glycemic control with CPAP, however, have been limited by small sample sizes, short durations of treatment, variable adherence among participants, or absence of a control group [2].

The purpose of this pilot study was to investigate the effect of active versus sham CPAP therapy on glycemic control and variability (GV) using CGM in patients with T2D and previously untreated OSA.

Correspondence to: Elena M Morariu.

Author contributions

E.M. was involved in statistical analysis, interpretation of data, and wrote the manuscript. P.J. was involved in conception and design and reviewed the manuscript. E.C. was involved in conception and design, statistical analysis and interpretation of data, and reviewed the manuscript. M.K. was involved in conception and design, interpretation of data, and writing and editing the manuscript.

Conflict of interest

Patrick Strollo has received grant support from and has been a consultant for Inspire Medical Systems, ResMed, Jazz Pharmaceuticals, and Philips Respironics. Philips Respironics provided equipment for the study, as disclosed by Eileen Chasens. Authors Elena Morariu and Mary Korytkowski have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

This prospective study was approved by the Institutional Review Board at the University of Pittsburgh. All patients provided written informed consent prior to participation. Consented subjects ($n = 23$) with T2D, not on insulin, with HbA1c $< 9\%$ (75 mmol/mol), with an apnea hypopnea index (AHI) ≥ 10 were randomly assigned to receive active ($n = 12$) or sham ($n = 11$) CPAP for 30 days. Body mass index (BMI) was obtained as weight in kilogram divided by the height in meters squared. Baseline measures of insulin sensitivity were calculated using homeostasis model assessment of insulin resistance (HOMA-IR). Changes in glycemic control were determined using the following measures performed at baseline and days 27–30 of assigned CPAP therapy: serum fructosamine, home blood glucose monitoring (BGM) performed four times per day before meals and bedtime, and 3 days of CGM (Medtronic; Minneapolis, MN). GV was determined as standard deviation (SD) and BG range during CGM.

The clinical characteristics of participants grouped according to CPAP assignment are summarized in the table. There were no group differences for age, gender, BMI (kg/m^2), HbA1c, fructosamine, or HOMA-IR (Table 1). Despite higher baseline AHI in the active CPAP group ($p = 0.04$), adherence to assigned therapy was similar. Subjects were effectively blinded to the therapy they received, with 58 % of active and 46 % of sham participants indicating that they were receiving real CPAP ($p = 0.54$). Serum fructosamine decreased with active (264.5 ± 36.9 $\mu\text{mol/L}$ vs. 253 ± 42 $\mu\text{mol/L}$, $p = 0.01$), but not sham CPAP (265.2 ± 46.5 $\mu\text{mol/L}$ vs. 270 ± 47.8 $\mu\text{mol/L}$, $p = 0.88$). A moderate effect size was observed for the reduction in fructosamine with active CPAP compared to sham CPAP (Cohen's $D = -0.74$). There was a larger effect size for the observed improvement in AHI with active vs. sham CPAP (Cohen's $D = -1.67$) (Table 1). No differences were observed in CGM mean BG 6a–6p with active CPAP (before vs. after: 8.2 ± 1.3 vs. 8.5 ± 2 mmol/L, $p = 0.6$) which differed from sham treatment where an increase in mean BG was observed (7.3 ± 2 vs. 8.4 ± 1.9 mmol/L, $p = 0.018$). Similar results were observed for home BGM (active CPAP: 8.2 ± 1.7 vs. 8.1 ± 1.4 mmol/L, $p = 0.84$) and (sham CPAP: 7.2 ± 1.7 vs. 8.4 ± 1.9 mmol/L, $p = 0.018$), respectively. No group differences were observed for any other CGM measures or GV (Table 1).

We observed subtle improvements in glycemic measures in subjects with T2D and OSA treated with active versus sham CPAP for 30 days as determined using serum fructosamine but not CGM. This discrepancy is likely due in part to the fact that fructosamine is a measure of glycemia over a 30-day period while CGM reflects only a 72-h period of time. The absence of any improvement in glycemic measures using BGM or CGM may also have been due in part to the fact that participants were under good glycemic control on oral agents alone at baseline as measured by HbA1c. Participants were effectively blinded to assigned therapies, demonstrating the feasibility of randomly assigning subjects to sham CPAP. The observed deterioration in glycemic measures in those receiving sham CPAP supports earlier findings demonstrating that active CPAP improves compliance with diabetes self-management practices which contributes to maintaining overall metabolic control [5]. The results of this pilot study need to be interpreted with caution given the small sample size and the group differences in baseline AHI measures. A larger randomized controlled clinical trial is currently being conducted.

Acknowledgments

Funding

The National Heart, Lung, and Blood Institute (NHLBI) provided financial support in the form of NHLBI 1 R21 HL 089522-01A2.

References

1. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? *Front Neurol.* 2012; 3:126. [PubMed: 23015803]
2. Feng Y, Zhang Z, Dong ZZ. Effects of continuous positive airway pressure therapy on glycaemic control, insulin sensitivity and body mass index in patients with obstructive sleep apnoea and type 2 diabetes: a systematic review and meta-analysis. *NPJ Prim Care Respir Med.* 2015; 25:15005. [PubMed: 25719929]
3. Dawson A, Abel SL, Loving RT, Dailey G, Shadan FF, Cronin JW. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. *J Clin Sleep Med.* 2008; 4:538–542. [PubMed: 19110882]
4. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. *Arch Intern Med.* 2005; 165:447–452. [PubMed: 15738376]
5. Chasens ER, Korytkowski M, Sereika SM, Burke LE. Effect of poor sleep quality and excessive daytime sleepiness on factors associated with diabetes self-management. *Diabetes Educator.* 2013; 39:74–82. [PubMed: 23192600]

Table 1

Baseline characteristics and CGM measures before and after active and sham CPAP

	Active CPAP			Sham CPAP			<i>p</i>
Age (year)	58 ± 12			53 ± 11			0.5
Gender (% male)	46 %			57 %			0.6
BMI (kg/m ²)	35.5 ± 6.3			34.9 ± 4.3			0.8
HbA1c % mmol/mol	6.6 ± 0.5 48 ± 5.5			6.9 ± 1 52 ± 10.9			0.3
HOMA-IR	3.8 ± 3			4.8 ± 4.5			0.9
Adherence (h)	4.1 ± 2.9			4.5 ± 2.7			0.8
	Pre	Post	Mean difference	Pre	Post	Mean difference	<i>p</i> *
AHI	56.6 ± 29.8	7.0 ± 6.2	-49.1 ± 26.3	25.6 ± 11.4	21.3 ± 15.4	-4.3 ± 15.8	<0.001
CGM mean BG (mmol/L)	8.1 ± 1.5	8.5 ± 2.2	0.4 ± 2.1	7.4 ± 2	7.9 ± 1.5	0.5 ± 0.7	0.7
SD (mmol/L)	1.7 ± 0.7	1.8 ± 0.9	0.2 ± 0.4	1.6 ± 0.6	1.7 ± 0.7	0.2 ± 0.6	0.9
CGM BG range (mmol/L)	8.5 ± 3.2	9.3 ± 4	0.7 ± 2.4	8.0 ± 2.8	8 ± 3.1	0.1 ± 3.7	0.7
% time BG 3.9–10 mmol/L	80.6 ± 20.3	76 ± 24.5	-5 ± 22	80.1 ± 16.3	85.1 ± 19.5	5 ± 16.7	0.4
% time BG > 10 mmol/L	18.1 ± 20.8	23.1 ± 24.5	4.5 ± 19.6	13.1 ± 15.7	14.9 ± 19.5	1.7 ± 6.7	0.7

* Refers to group differences in pre vs. post data